Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026

Phase 2positiveleniolisibPositive

AI Analysis

Summary

Pharming announced positive Phase II topline data for leniolisib in patients with genetic PIDs with immune dysregulation, presented at ESID 2026. The positive data readout represents a meaningful advancement in the development program for this immunology candidate.

Clinical Trial Data

Phase

Phase II

Outcome Details

positive Phase II topline data

Importance:7/10

Sentiment:

0.75

Phase 2 dataimmunologyrare diseaseconference presentation

Related Companies

$PHAR

Read the original article

Published by yahoo_finance on October 14, 2026 6:00 AM

Read Original